Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.
Neal D. Shore, MD, FACS
Advertisement
Articles by Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.
Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.
Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.
Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.
Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.
Advertisement
Latest Updated Articles
Dr. Shore on Immunotherapy Targeting PSA and PSMA in Biochemically Recurrent Prostate CancerPublished: June 22nd 2020 | Updated:
Dr. Shore on the Need for Further Education on Molecular Testing in mCRPCPublished: October 29th 2020 | Updated:
Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)Published: September 29th 2023 | Updated:
Dr. Neal Shore on Treatment of Elderly Patients With mCRPCPublished: September 14th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5